Adalimumab
💊 Brand Formulations & Prices
6 brands sorted by unit price
Adimab
Advixa
Adali
Adalimab
Yuflyma
Hyrimoz
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesAdali injection is a tumor necrosis factor (TNF) blocker indicated for treatment of:
Rheumatoid Arthritis (RA)
: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA
... Read more
Adali injection is a tumor necrosis factor (TNF) blocker indicated for treatment of:
Rheumatoid Arthritis (RA)
: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA
Juvenile Idiopathic Arthritis (JIA)
: Reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older
Psoriatic Arthritis (PsA)
: Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA
Ankylosing Spondylitis (AS)
: Reducing signs and symptoms in adult patients with active AS
Adult Crohn’s Disease (CD)
: Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy. Reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab
Pediatric Crohn’s Disease
: Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate
Ulcerative Colitis (UC)
: Inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine or 6-mercaptopurine (6-MP). The effectiveness of Adali has not been established in patients who have lost response to or were intolerant to TNF blockers
Plaque Psoriasis (Ps)
: The treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate
Hidradenitis Suppurative (HS)
: The treatment of moderate to severe hidradenitis suppurativa
Adalimumab should not be administered to patients with known hypersensitivity to Adalimumab or any of its components.
The most common adverse reaction with Adali was injection site reactions (erythema and/or itching, hemorrhage, pain or swelling). The most common adverse reactions leading to discontinuation of Adali in rheumatoid arthritis were clinical flare reaction, rash and pneumonia.
Other adverse reactions of Adali includes- Gastrointestinal disorders: Diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis.
General disorders and administration site conditions: Pyrexia.
Hepato-biliary disorders: Liver failure, hepatitis.
Immune system disorders: Sarcoidosis.
Neoplasms benign, malignant and unspecified (including cysts and polyps): Merkel Cell Carcinoma (neuroendocrine carcinoma of the skin).
Nervous system disorders: Demyelinating disorders (e.g., optic neuritis, Guillain-Barré syndrome).
Cerebrovascular accident Respiratory disorders: Interstitial lung disease, including pulmonary fibrosis.
Pulmonary embolism Skin reactions: Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all sub-types including pustular and palmoplantar), alopecia.
Vascular disorders: Systemic vasculitis, deep vein thrombosis.
Serious infections
: Adali should not be started during an active infection. If an infection develops, should be carefully monitored and if infection becomes serious Adali should be stopped.
Invasive fungal infections
: For patients who develop a systemic illness on Adali, empiric antifungal therapy should be considered for those who reside or travel to regions where mycoses are endemic
Malignancies
: Incidence of malignancies was greater in Adali-treated patients than in controls
Anaphylaxis or serious allergic reactions
may occur Hepatitis B virus reactivation: HBV carriers should be monitored during and several months after therapy. If reactivation occurs, Adali should be stopped and antiviral therapy should be started
Demyelinating disease
: Exacerbation or new onset, may occur Cytopenias, pancytopenia: Patients should be advised to seek immediate medical attention if symptoms develop, and should be considered stopping Adali
Heart failure
: Worsening or new onset, may occur
Lupus-like syndrome
: Adali should be stopped if syndrome develops
Adalimumab is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated levels of TNF are found in the synovial fluid of patients with Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased levels of TNF are also found in psoriasis plaques. In Plaque Psoriasis, treatment with Adalimumab may reduce the epidermal thickness and infiltration of inflammatory cells.